Impact and predictors of readmission in hypercalcemia of malignancy: Findings of a nationwide analysis
| Autor: | Shristi Upadhyay, Fred R. Rosen, Binav Baral, Victor Prado, Estefania Gauto, Miguel Salazar, Trilok Shrivastava, Navika Chhabra |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 39:e18809-e18809 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2021.39.15_suppl.e18809 |
| Popis: | e18809 Background: Hypercalcemia of malignancy (HCM) is common in cancer. It is a sign of advanced malignancy and associated with poor outcomes. Although a well-known phenomenon, treatment options are limited and recurrence leading to readmissions is common, increasing morbidity and mortality. We attempt to explore the mortality, healthcare resource utilization, 30-day readmission rate and independent predictors of readmission for HCM. Methods: We queried the 2017 National Readmission Database (NRD) of adults readmitted within 30 days after index admission for HCM with a concomitant diagnosis of solid tumors. T test was used for continuous variables and chi square test was used for categorical variables. Multivariate regression was used to identify predictors for unplanned readmissions. Results: A total of 14,323 patients with solid tumors were admitted with HCM. The 30-day readmission rate was 24.9%. Common causes for readmission were sepsis, respiratory failure, hypercalcemia, distant metastases and AKI. At 30 days, readmitted patients were less likely to be discharged compared to patients admitted initially due to hypercalcemia (27.4 vs 30.8%; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|